A model defined by Jason Karlawish, MD, Associate Professor of Medicine and Medical Ethics at the University of Pennsylvania School of Medicine, involves clinicians continuously gathering risk factor information – from a patient’s medical history, electronic medical records or recent office visit – and combining it with clinical studies about disease risk. Once the patient’s risk has been assessed, the physician can provide the appropriate intervention to prevent the onset of disease, rather than treat the disease once it is fully developed.

Novartis says it plans to submit its microchip containing ‘smart-pill’ technology to European regulators within 18 months. Novartis is currently using the technology on an already-approved drug used to prevent organ rejection in transplant patients , but is looking at incorporating the sensor-based technology into other medications for which compliance is critical, such as cardiovascular and oncology drugs.

McKesson Pharmacy Systems LLC (MPS), a software division of McKesson Corporation, announced the launch of EnterpriseRx™ Reports Director at the 2010 National Association of Chain Drug Stores (NACDS) Pharmacy Technology Show. Reports Director is the latest solution to be added to EnterpriseRx, the leading pharmacy management system among large retail chains today.